Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Dechant

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Deutsche Medizinische Wochenschrift (1946)|May 29, 2018
[Thrombotic Microangiopathies]Jörg Schubert, Michael Dechant
Mabs|January 14, 2010
Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodiesMatthias Peipp, Michael Dechant, Thomas Valerius
Seminars in Oncology|August 27, 2003
HLA class II antibodies in the treatment of hematologic malignanciesMichael Dechant, Joerg Bruenke, Thomas Valerius
Current Opinion in Immunology|July 1, 2008
Effector mechanisms of therapeutic antibodies against ErbB receptorsMatthias Peipp, Michael Dechant, Thomas Valerius
Archivum Immunologiae Et Therapiae Experimentalis|May 29, 2010
Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodiesStefan Lohse, Matthias Peipp, Thomas Beyer, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|March 30, 2021
[Treatment of Opioid-dependent Inmates - Attitudes and Treatment Practice of medical Staff in Bavarian Prisons]Maren Weiss, Kerstin Geißelsöder, Maike Breuer, et al.
Nordisk Alkohol- & Narkotikatidskrift : NAT|November 20, 2024
Opioid substitution treatment, relapse and addiction-related outcomes in prison setting and after release: A longitudinal studyKerstin Geißelsöder, Maren Weiss, Klara Boksán, et al.
Leukemia & Lymphoma|October 31, 2006
A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot studyJuergen Rech, Roland Repp, Dorit Rech, et al.
British Journal of Haematology|January 9, 2013
An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levelsThies Rösner, Stefanie Derer, Christian Kellner, et al.
Human Immunology|November 24, 2004
Detection and specification of noncomplement binding anti-HLA alloantibodiesMarie-Luise Arnold, Thorsten Zacher, Michael Dechant, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Deutsche Medizinische Wochenschrift (1946)|May 29, 2018
[Thrombotic Microangiopathies]Jörg Schubert, Michael Dechant
Mabs|January 14, 2010
Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodiesMatthias Peipp, Michael Dechant, Thomas Valerius
Seminars in Oncology|August 27, 2003
HLA class II antibodies in the treatment of hematologic malignanciesMichael Dechant, Joerg Bruenke, Thomas Valerius
Current Opinion in Immunology|July 1, 2008
Effector mechanisms of therapeutic antibodies against ErbB receptorsMatthias Peipp, Michael Dechant, Thomas Valerius
Archivum Immunologiae Et Therapiae Experimentalis|May 29, 2010
Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodiesStefan Lohse, Matthias Peipp, Thomas Beyer, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|March 30, 2021
[Treatment of Opioid-dependent Inmates - Attitudes and Treatment Practice of medical Staff in Bavarian Prisons]Maren Weiss, Kerstin Geißelsöder, Maike Breuer, et al.
Nordisk Alkohol- & Narkotikatidskrift : NAT|November 20, 2024
Opioid substitution treatment, relapse and addiction-related outcomes in prison setting and after release: A longitudinal studyKerstin Geißelsöder, Maren Weiss, Klara Boksán, et al.
Leukemia & Lymphoma|October 31, 2006
A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot studyJuergen Rech, Roland Repp, Dorit Rech, et al.
British Journal of Haematology|January 9, 2013
An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levelsThies Rösner, Stefanie Derer, Christian Kellner, et al.
Human Immunology|November 24, 2004
Detection and specification of noncomplement binding anti-HLA alloantibodiesMarie-Luise Arnold, Thorsten Zacher, Michael Dechant, et al.
Pageof 3